State government solutions | Building healthier communities - Prime Therapeutics
Build healthier communities
Expertise and choice in Medicaid delivery models
With 40+ years of Medicaid pharmacy experience, Prime Therapeutics (Prime) provides person-centered support to 54 million Americans enrolled in state government programs. By partnering with Prime, you’ll get the expertise and flexibility you need to help control costs and optimize member care. We provide:
Traditional Fee-for-Service (FFS) models
Medicaid pharmacy benefits carved out of managed care organization (MCO) agreements
PBM services in which we contract with your state Medicaid program and MCOs
Differentiated programs that meet your needs
Flexible POS solution
Market-leading PDL programs
We implemented the country’s first Medicaid FFS preferred drug list (PDL) program in 2001. As pioneers in this space, we offer individual state PDL programs and manage two CMS-approved Medicaid supplemental rebate pools, National Medicaid Pooling Initiative and The Optimal PDL $olution.
Rebate management
We help states successfully implement and operate within the Medicaid Drug Rebate Program, invoicing manufacturers so states see maximum rebates. And we pass through to our state clients 100% of rebates collected.
ADAP
We have 25 years of experience administering ADAPs to meet state needs. With our ADAPs, you’ll receive an efficient and cost-effective program that helps ensure patients living with HIV/AIDS can access lifesaving medications.
Partnering with Medicaid to manage PADs
Managing chronic conditions with care
People living with chronic conditions and the providers who treat them face unique challenges. One of the most prevalent chronic conditions is diabetes, affecting up to 14.7% of Americans.4 We support Medicaid FFS plans and members by managing the cost of diabetic supplies through our multistate Diabetic Supply Program supplemental rebate pool.
Tackling the challenges of high-cost PADs
Footnotes
1 U.S. Food & Drug Administration. (2023, December 8). FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease. https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease